Bcl-2 is an antiapoptotic protein expressed in a wide variety of cell types. We have found that overexpression of bcl-2 in PC12 neural crest tumor cells leads to increased expression of neural differentiation-associated genes and decreased expression of proliferation-related genes. Culture growth rate decreases as well. Overexpression of bcl-2 also leads to increased expression of TrkA and increased phosphorylation of signal transductants in, albeit not specific for, the TrkA-MEK-ERK pathway. Blocking of NGF-mediated signaling through TrkA prevents Bcl-2-associated expression changes in differentiation-associated genes, raising the possibility that Bcl-2 mediates induction of neural differentiation through TrkA/NGF signaling.
Bcl-2 is the founding member of a family of antiapoptotic proteins. While it is best known for its function in this regard, Bcl-2 has been implicated in neurite outgrowth. (Oh et al., 1996; Zhang et al., 1996; Middleton et al., 1998; Suzuki and Tsutomi, 1998) . The mechanism by which Bcl-2 exerts this effect and the sequence of molecular events that underlie this morphological change are not known. We now implicate the neurotrophin receptor, TrkA, and its cognate ligand, nerve growth factor (NGF), in this effect. We further define the molecular markers of and signaling events involved in this process.
Microarray comparison of stable mock-and bcl-2 transfectants (Kane et al., 1993) of PC12 cells done in duplicate demonstrated upregulation of chromogranin B, secretogranin III, synaptosomal-associated 91 kDa protein, cathepsin, neurospecific gene family membrane proteins 1 and 2, neuronatin, and cadherin-related neuronal receptor protein 1 (Table 1) in bcl-2-transfected cells relative to their mock-transfected counterparts. All of these proteins are known to be associated with differentiation along a neuronal lineage (Joseph et al., 1995 (Joseph et al., , 1996 Fujita and Kurachi, 2000; Hamada and Yagi, 2001; Huttunen et al., 2002; Rong et al., 2002) . In addition, downregulation of growth-associated protein 43 (GAP43), transforming growth factor-beta (TGF-b), fibroblast growth factor (FGF), N-myc downstream regulated protein 1 and insulin-like growth factor binding protein (IGFBP-6) suggested inhibition of proliferation (Grellier et al., 1998; Boilly et al., 2000; Bottner et al., 2000; Kalaydjieva et al., 2000; Mani et al., 2001) in bcl-2-transfected cells. All of these changes were confirmed by Northern blot with GAPDH mRNA as a loading standard, and decreased expression of proliferation-related genes was quantified by densitometry ( Figure 1a,b) . Western blot analysis using b-tubulin as a loading standard confirmed increased levels of the neural differentiation-associated protein SAP-25 and the vesicular monoamine transporter (VMAT) in bcl-2-transfected cells (Figure 1c) . Furthermore, the bcl-2 transfectants grow more slowly in culture than their mock-transfected counterparts (Figure 1d ).
While microarray studies can demonstrate changes in cellular gene expression after molecular manipulation, they cannot distinguish between primary and secondary changes. As PC12 cells are known to differentiate along neural lines in response to NGF (Greene, 1978) , we determined the expression level of NGF and protein content of its high-and low-affinity receptors, TrkA and p75, respectively, in mock-and bcl-2-transfected PC12 cells. Both mock-and bcl-2-transfected PC12 cells make NGF mRNA detectable by RT-PCR amplification followed by Northern blot (Figure 2a ). NGF mRNA is detectable at comparable levels in the two transfectants. Western blot analysis also revealed markedly increased levels of TrkA in bcl-2 transfectants relative to their mock-transfected counterparts ( Figure 2b ).
In order to examine the roles of endogenous and exogenous NGF and their signaling through TrkA in induction of the differentiated, neural molecular phenotype of the bcl-2-transfected PC12 cells, we first maintained these cells for 3 days in serum-free, N2-supplemented DMEM. SAP-25 expression does not change under these conditions (Figure 3 ), most likely because of the endogenous NGF produced by both transfectants. However, addition of anti-NGF antibodies to the medium diminishes SAP-25 expression. The tyrosine hydroxylase inhibitor, K252a, also decreased SAP-25 expression, as did the antibody, NGF30, that blocks NGF binding to the p75 receptor (Saragovi et al., 1998) , in turn a facilitator of the TrkA-NGF interaction. These results suggest that Bcl-2 could act primarily in PC12 cells to increase TrkA expression, and that increased TrkA signaling could, in turn, result in induction of differentiation in these cells. Alternatively, increased expression of TrkA could be one of several independent markers of Bcl-2-induced differentiation of PC12 cells.
NGF/TrkA-mediated differentiation of neural crest cells is thought to proceed through activation of the TrkA-MEK-ERK1/2 pathway, although activation of this pathway is not TrkA-specific (Vaudry et al., 2002; Yan et al., 2002) . As is shown in Figure 4 , phosphorylation of TrkA, MEK, and ERK1 is indeed enhanced in bcl-2-transfected relative to mock-transfected PC12 cells. Activation of ERK and downstream JNK has previously been demonstrated in bcl-2-transfected PC12 cells (Schwartz et al., 2002) . Bcl-2 is best known for its antiapoptotic function. However, in PC12 cells stably transfected with bcl-2, it has been shown paradoxically to potentiate apoptosis induction by the antimitotic chemotherapeutic agent, neocarzinostatin (Cortazzo and Schor, 1996) , by enhancing sulfohydryl-mediated activation of this drug (Schor et al., 2000) and by serving as the precursor of a proapoptotic protein formed by its caspase 3-mediated cleavage . We now document the differentiative effects of Bcl-2. Previous reports (Oh et al., 1996; Zhang et al., 1996; Middleton et al., 1998; Suzuki and Tsutomi, 1998) have described enhancement or induction of neurite extension in PC12 and other neural crest cells related to expression of bcl-2. The use of microarray technology has enabled us to define these effects of bcl-2 overexpression in molecular terms, and to raise the possibility of the primacy of TrkA/NGF and the TrkA-MEK-ERK1/2 pathway in Bcl-2-mediated neural differentiation.
